Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1) R132C and R132H variants, is approved for the treatment of acute myeloid leukaemia (AML). Resistance to ivosidenib due to a second site mutation of IDH1 R132C, leading to IDH1 R132C/S280F, has emerged. We describe biochemical, crystallogr...
Үндсэн зохиолчид: | Reinbold, R, Hvinden, IC, Rabe, P, Herold, RA, Finch, A, Wood, J, Morgan, M, Staudt, M, Clifton, IJ, Armstrong, FA, McCullagh, JSO, Redmond, J, Bardella, C, Abboud, MI, Schofield, CJ |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Springer Nature
2022
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
-н: Raphael Reinbold, зэрэг
Хэвлэсэн: (2022-08-01) -
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
-н: Hvinden, IC, зэрэг
Хэвлэсэн: (2021) -
Isocitrate dehydrogenase gene variants in cancer and their clinical significance
-н: Cadoux-Hudson, T, зэрэг
Хэвлэсэн: (2021) -
Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1
-н: Liu, S, зэрэг
Хэвлэсэн: (2021) -
Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors
-н: Liu, S, зэрэг
Хэвлэсэн: (2023)